Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Mastocytosis, Systemic × Denosumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 20 Neoplasms 11 Prostatic Neoplasms 8 Multiple Myeloma 7 Neoplasm Metastasis 6 Giant Cell Tumor of Bone 5 Osteoporosis 4 Fractures, Bone 4 Kidney Neoplasms 3 Carcinoma, Renal Cell 3 Bone Diseases, Metabolic 3 Spinal Cord Compression 2 Smoldering Multiple Myeloma 2 Recurrence 2 Parathyroid Neoplasms 2 Melanoma 2 Lymphoma 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Bone Neoplasms 2 Bone Diseases 2 Bone Cysts, Aneurysmal 2 With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer Metastatic 1 Paraproteinemias 1 Ovarian Neoplasms 1 Osteosarcoma 1

Interventions

avapritinib 3 midostaurin 2 masitinib 2 Imatinib Mesylate 2 sarilumab 1 ripretinib 1 obatoclax 1 nilotinib 1 ibrutinib 1 denileukin diftitox 1 Thalidomide 1 Everolimus 1 Denosumab 1 Dasatinib 1 Cladribine 1 Brentuximab Vedotin 1 AK002 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03401060 2024-05-03

DenosuMast

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed

Osteoporosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡